Online inquiry

IVTScrip™ mRNA-Anti-HGF, AV-299(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3438MR)

This product GTTS-WQ3438MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets HGF gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000601.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3082
UniProt ID P14210
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-HGF, AV-299(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ3438MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15572MR IVTScrip™ mRNA-Anti-AXL, UNII-FFX71LCS5T(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA UNII-FFX71LCS5T
GTTS-WQ10254MR IVTScrip™ mRNA-Anti-MS4A1, LFB-R603(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA LFB-R603
GTTS-WQ12511MR IVTScrip™ mRNA-Anti-MUC5AC, NOE-102(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA NOE-102
GTTS-WQ13178MR IVTScrip™ mRNA-Anti-TNFRSF4, PF-04518600(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA PF-04518600
GTTS-WQ3600MR IVTScrip™ mRNA-Anti-LYPD3, BAY 1129980(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA BAY 1129980
GTTS-WQ12708MR IVTScrip™ mRNA-Anti-DLL4&VEGFA, OMP-305B83(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA OMP-305B83
GTTS-WQ2998MR IVTScrip™ mRNA-Anti-KDR, Angiocept(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA Angiocept
GTTS-WQ2517MR IVTScrip™ mRNA-Anti-CALCRL, AMG 334(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AMG 334
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW